TDF/3TC for PrEP: The Rationale and the Evidence
By Dr. Ioannis Hodges-Mameletzis, World Health Organization
Toward Medicaid Prescription Drug Cost Savings in New York State
By Tim Horn, Director, Medication Access and Pricing, NASTAD
On January 17, 2019, Treatment Action Group and Housing Works presented this webinar discussing current advocacy to cut costs by scaling up the use of Mylan’s Cimduo (TDF/3TC) and Symfi (EFV/TDF/3TC) as part of New York State Medicaid. Tim Horn from NASTAD walked webinar participants through the recent FDA approval of Cimduo, Symfi, and Symfi Lo and the advantages of increasing their usage by Medicaid beneficiaries without compromising safety or efficacy for many people living with HIV. Ionnis Hodges-Mameletzis from the World Health Organization also walked webinar participants through the suitability of Cimduo (TDF/3TC) for PrEP based upon his extensive work on the topic at WHO. The discussion was moderated by TAG’s Jeremiah Johnson.
Following the webinar, TAG and Housing Works sought sign ons from New York State organizations for a letter requesting that Cimduo and Symfi be included on the preferred drug list (PDL) for treatment, that Cimduo be included for PEP, and that Cimduo be considered for inclusion as PrEP.
Below you’ll find the presentations used at the webinar, along with full recording. If you have any questions ahead of time please email Jeremiah at Jeremiah.Johnson@treatmentactiongroup.org.